Robert Leisk has joined Biokinetics as a senior vice president responsible for international biopharmaceutical business development for projects emanating from North America.
Robert Leisk has joined Biokinetics as a senior vice president responsible for international biopharmaceutical business development for projects emanating from North America. Leisk has been in the biopharmaceutical industry for over 25 years, having worked for leading global design and construction firms. He has supported numerous clients and their projects in Europe, Asia, and the Americas. Robert has a bachelor of science degree in civil engineering and has completed the executive MBA program from the London School of Economics.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.